2012 DoSER Annual Holiday Lecture
Almost 200 people joined DoSER on December 13 for the 2012 Annual Holiday Lecture which explored the complex relationship between genes and human identity. Renowned molecular biologist and scholar of science and religion, Denis Alexander, described recent advances in developmental biology, genomics, epigenetics and behavioral genetics, including the flurry of publications describing results from the Encyclopedia of DNA Elements (ENCODE) consortium, and discussed their implications for notions of human freedom and responsibility. Journalist Steve Paluson responded with a discussion of the similar issues raised by developments in the field of neuroscience.

By: wwwAAASorg

Read more:
2012 DoSER Annual Holiday Lecture - Video

Recommendation and review posted by Bethany Smith

SALT LAKE CITY, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) today announced results for its second fiscal quarter ended December 31, 2012. Revenue for the second fiscal quarter increased 21 percent over the same period in the prior year to $149.1 million. Second fiscal quarter earnings per diluted share were $0.42, an increase of 27 percent over the same period of the prior year.

"We are pleased with the Company's continued strong financial performance since this represents our sixth consecutive quarter of top line growth exceeding 20 percent," said Peter D. Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "Myriad remains dedicated to driving revenue growth based on our three major strategic initiatives of expanding our existing markets, extending our international presence, and launching new products."

Second Fiscal Quarter 2013 Results

Year-to-Date Performance

Business Highlights during the Second Quarter of Fiscal 2013

Myriad Announces New $200 Million Share Repurchase Program

Myriad is also announcing today that its Board of Directors has authorized a new $200 million stock repurchase program. "This decision is reflective of Myriad Genetics commitment to maintaining a balanced capital deployment strategy," said Jim Evans, Chief Financial Officer of Myriad Genetics, Inc.

Repurchases under the $200 million authorization will be made through open market or privately negotiated purchases as determined by the Company's management. The amount and timing of stock repurchases will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.

Fiscal Year 2013 Outlook

The Company is tightening its revenue expectations for fiscal year 2013 financial performance. Total revenue is now expected to be in a range of $575 million to $585 million, an increase to the lower end of the previous guidance range of $570 million to $585 million. This represents 16 percent to 18 percent growth over our prior fiscal year. The Company is also increasing its guidance for fiscal year 2013 diluted earnings per share to $1.55 to $1.58, up from the previous guidance of $1.50 to $1.55 per share. The new range represents 19 percent to 21 percent growth over fiscal year 2012 diluted EPS. These projections are forward looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release. The Company will provide further detail on its business outlook during the conference call it is holding today to discuss its fiscal 2013 second quarter financial results.

View post:
Myriad Genetics Reports Second Quarter Fiscal Year 2013 Results

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwire - Feb 5, 2013) - Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, announced today that Kyle Guse, CFO and General Counsel, will present the Company's business model, products and services, and investment thesis at the FSX Dallas Conference at the Ritz Carlton Dallas Hotel in Dallas, Texas, on Friday, February 8, 2013, beginning at 9:49 am Central Time.

Mr. Guse stated, "I believe Atossa Genetics offers investors an exciting opportunity to participate in the upside potential of our products and services focused on breast health. The recently announced national launch of the ForeCYTE Breast Health Test is one of several key milestones that position Atossa for accelerated growth in 2013 and beyond."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa's plans, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services and other risks detailed from time to time in the Atossa's final prospectus, dated November 7, 2012, filed with the U.S. Securities and Exchange Commission.All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Read more here:
Atossa Genetics to Present at the FSX Dallas Investor Conference

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced the initiation of two phase I clinical trials of SGN-CD19A, one for patients with B-cell acute lymphoblastic leukemia (ALL) and one for patients with B-cell non-Hodgkin lymphomas. SGN-CD19A utilizes Seattle Genetics industry-leading antibody-drug conjugate (ADC) technology. The trials are designed to assess the safety and antitumor activity of SGN-CD19A, an ADC targeted to CD19.

CD19 is expressed in a variety of hematologic malignancies, including non-Hodgkin lymphoma and ALL, and has limited expression on normal tissues making it an ideal ADC target. Our preclinical data indicate that SGN-CD19A internalizes rapidly into tumor cells, resulting in targeted cell killing, said Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine at Seattle Genetics. Our SGN-CD19A clinical development program comprises two trials that, together, will provide a robust understanding of the activity and tolerability of this ADC in patients with aggressive CD19-positive lymphomas or ALL. In addition to the five ADCs already in ongoing clinical trials, we plan to advance two additional ADC programs into the clinic during 2013, underscoring our leadership in the field.

The studies are phase I, open-label, dose-escalation clinical trials. The primary endpoints are to estimate the maximum tolerated dose and to evaluate the safety of SGN-CD19A. In addition, the trials will evaluate antitumor activity, pharmacokinetics, progression-free survival and overall survival. One trial will enroll adult and pediatric patients with relapsed or refractory B-cell ALL, as well as patients with Burkitt lymphoma or leukemia or B-cell lymphoblastic lymphoma. The dose escalation portion of the study is designed to evaluate both weekly and every three week schedules and will enroll approximately 80 patients at multiple centers in the United States. A second trial will enroll patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. The dose escalation portion of the trial will evaluate SGN-CD19A administered every three weeks and will enroll approximately 25 patients at multiple centers in the United States.

Both trials permit additional patients to be enrolled into expansion cohorts following determination of the maximum tolerated dose.

For more information about the trials, including enrolling centers, please visit http://www.clinicaltrials.gov.

About SGN-CD19A

SGN-CD19A is an ADC composed of an anti-CD19 antibody attached to a synthetic cytotoxic cell-killing agent, monomethyl auristatin F (MMAF), using Seattle Genetics proprietary technology. The ADC is designed to be stable in the bloodstream, and to release its cytotoxic agent upon internalization into CD19-expressing cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing the antitumor activity.

About Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia, also called acute lymphocytic leukemia or ALL, is an aggressive type of cancer of the bone marrow and blood that progresses rapidly without treatment. In ALL, lymphoblasts, which are malignant, immature white blood cells, multiply and crowd out normal cells in the bone marrow. ALL is the most common type of cancer in children. According to the American Cancer Society, approximately 6,000 people were to be diagnosed with ALL during 2012 and more than 1,400 would die from the disease.

More here:
Seattle Genetics Initiates Two Phase I Trials of SGN-CD19A

Recommendation and review posted by Bethany Smith

Beth H. T-11 Incomplete Spinal Cord Injury Power Plate Training
http://www.pressingontx.org - Pressing On client Beth H. working on the Power Plate. Great job!

By: pressingontx

Read more here:
Beth H. T-11 Incomplete Spinal Cord Injury Power Plate Training - Video

Recommendation and review posted by sam

Feb. 4, 2013 By broadly comparing the DNA of children to that of elderly people, gene researchers have identified gene variants that influence lifespan, either by raising disease risk or by providing protection from disease.

"This research is the first genome-wide, population-based study of copy number variations in children associated with human longevity," said study leader Hakon Hakonarson, MD, PhD, director of the Center for Applied Genomics at The Children's Hospital of Philadelphia.

The study appeared Jan. 30 in the open-access journal PLOS ONE.

Copy number variations (CNVs) are rare but play important role in raising or lowering disease risk

Copy number variations (CNVs) are losses or gains in DNA sequence that are usually rare, but which often play an important role in raising or lowering the risk of disease.

The study team compared the rates of CNVs in a sample of 7,313 young subjects, 18 years old and below, from the Children's Hospital network, to a group of 2,701 Icelandic subjects, 67 years old or above, recruited by the Icelandic Heart Association. The researchers used microchip arrays to perform the whole-genome CNV analyses.

"Our assumption was that CNVs appearing in children but not in the elderly were more likely to be disease-causing, while CNVs that were proportionately higher in older people were more likely to be protective, allowing them to live longer," said Hakonarson.

Study compared CNVs in children with CNVs in older people

After performing a replication study in an independent U.S. cohort of 2,079 children and 4,692 older people and making statistical adjustments to address population stratification, the study team found seven significant CNVs. Three of the CNVs were deletions of DNA sequence, while four were duplications.

The genes impacted by the CNVs were disproportionately involved in alternative splicing. This is an important biological mechanism in which, instead of one gene simply expressing one protein, modifications to messenger RNA result in different protein products based on the same underlying DNA code in a given gene.

See the article here:
Gene variants found to affect human lifespan

Recommendation and review posted by Bethany Smith

Personal Genome Sequencing: A Lecture by Marc S. Williams, MD
The Silverstein Lecture series is hosted by Northwestern University #39;s Center for Genetic Medicine twice annually. The winter 2013 lecture series, held on January 16 and 17, 2013, featured Marc S. Williams, MD, Director, Geisinger Health System Genomic Medicine Institute. Created by NUIT A RT NUAMPS (Northwestern University Advanced Media Production Studio)

By: NUFeinbergMed

Read the rest here:
Personal Genome Sequencing: A Lecture by Marc S. Williams, MD - Video

Recommendation and review posted by Bethany Smith

SAN DIEGO, Feb. 4, 2013 /PRNewswire/ -- Sequenom, Inc. (SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, announced today that the MaterniT21 PLUS laboratory-developed test (LDT) available exclusively through Sequenom Center for Molecular Medicine (Sequenom CMM) will now report as additional findings the presence of certain fetal sex chromosomal aneuploidies, in addition to its identification of autosomal aneuploidies for chromosome 21 (associated with Down syndrome), chromosome 18 (associated with Edwards syndrome), and chromosome 13 (associated with Patau syndrome). Reporting of these sex aneuploidies will begin for samples received as of Monday, February 4, 2013.

The test will report on the presence of four rare aneuploidies involving an abnormal number of X or Y chromosomes, including female syndromes 45,X (Turner Syndrome) and 47,XXX (Triple X Syndrome), and male syndromes 47,XXY (Klinefelter Syndrome) and 47,XYY. Results of the blinded clinical validation study set have been submitted for publication in a peer-reviewed journal.

"Sex chromosome abnormalities may be recognized at birth, as part of the spectrum of less severe chromosome abnormalities. They can also be found in adults, many being incidentally discovered in the course of evaluating patients for infertility or endocrine problems. Identifying these conditions through the MaterniT21 PLUS test will allow the health care provider and patient to discuss the medical issues associated with these conditions as well as to develop both short- and long-term care plans," said Allan Bombard, MD, Sequenom's Chief Medical Officer.

The MaterniT21 PLUS test analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA. The test is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks' gestation. Estimates suggest there are about 750,000 pregnancies at high risk for fetal aneuploidy each year in the United States. The MaterniT21 PLUS test is available exclusively through the Sequenom Center for Molecular Medicine (Sequenom CMM) as a testing service provided to physicians. To learn more about the test, please visit http://www.Sequenomcmm.com.

About Sequenom

Sequenom, Inc. (SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

About Sequenom CMM

Sequenom Center for Molecular Medicine (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests with a focus on prenatal and ophthalmological diseases and conditions. Branded under the name SensiGene, MaterniT21 PLUS, and RetnaGene, these molecular genetic laboratory tests provide early patient management information for obstetricians, geneticists and maternal fetal medicine specialists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

Forward-Looking Statement

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the expected publication and timing thereof of the validation data for the fetal sex chromosomal aneuploidies, the expected date of February 4, 2013 for reporting fetal sex chromosomal aneuploidies, the impact, benefits, and effect of identifying fetal sex chromosomal aneuploidies on patient care and planning, the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM changing the landscape in genetic disorder diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties such as, without limitation, healthcare providers, international distributors and licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 and its Annual Report on Form 10-K for the year ended December 31, 2011, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Read more from the original source:
Sequenom CMM's MaterniT21 PLUS LDT Now Reporting On Gender-Specific Chromosomal Abnormalities

Recommendation and review posted by Bethany Smith

London, Feb 5 (ANI): A tiny "genetic patch" can be used to prevent a form of deafness that runs in families, a new research has shown.

Patients with Usher syndrome have defective sections of their genetic code which cause problems with hearing, sight and balance.

A study showed the same defects could be corrected in mice to restore some hearing, the BBC reported.

Experts said it was an "encouraging" start.

There are many types of Usher syndrome tied to different errors in a patient's DNA - the blueprint for building every component of the body.

One of those mutations runs in families descended from French settlers in North America.

When they try to build a protein called hormonin, which is needed to form the tiny hairs in the ear that detect sound, they do not finish the job.

It results in hearing loss at birth and has a similar effect in the eye where it causes a gradual loss of vision.

Scientists at the Rosalind Franklin University of Medicine and Science, in Chicago in the US, designed a small strip of genetic material which attaches to the mutation and keeps the body's factories building the protein.

There has been something of a flurry of developments in restoring hearing in the past year.

View post:
Genetic patch cures deafness in newborn mice

Recommendation and review posted by Bethany Smith

Introduction to Mendelian Genetics (part 1)
Introduction to genetics for middle school science students.

By: graeme ritchie

View post:
Introduction to Mendelian Genetics (part 1) - Video

Recommendation and review posted by Bethany Smith

Lot23
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

Read more from the original source:
Lot23 - Video

Recommendation and review posted by Bethany Smith

Lot25
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

Originally posted here:
Lot25 - Video

Recommendation and review posted by Bethany Smith

Lot33
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

View post:
Lot33 - Video

Recommendation and review posted by Bethany Smith

Lot29
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

Continued here:
Lot29 - Video

Recommendation and review posted by Bethany Smith

Lot16
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

Visit link:
Lot16 - Video

Recommendation and review posted by Bethany Smith

genetics review 1
Review of genetics terms for quiz

By: bodescience

The rest is here:
genetics review 1 - Video

Recommendation and review posted by Bethany Smith

Lot50
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

Go here to see the original:
Lot50 - Video

Recommendation and review posted by Bethany Smith

Lot49
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

Here is the original post:
Lot49 - Video

Recommendation and review posted by Bethany Smith

Lot45
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

See original here:
Lot45 - Video

Recommendation and review posted by Bethany Smith

Lot44
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

View post:
Lot44 - Video

Recommendation and review posted by Bethany Smith

Lot43
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

Go here to see the original:
Lot43 - Video

Recommendation and review posted by Bethany Smith

Lot60
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

Read more here:
Lot60 - Video

Recommendation and review posted by Bethany Smith

Lot58
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

Read more from the original source:
Lot58 - Video

Recommendation and review posted by Bethany Smith

Lot57
Injemira Beef Genetics 42nd Annual Production Sale Thursday 21st February 2013

By: StudLiveStockSales

Read this article:
Lot57 - Video

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwire - Feb 4, 2013) - Atossa Genetics, Inc. ( NASDAQ : ATOS ) announced that its new ForeCYTE Breast Health System addresses the problem of detecting not only cancer, but also the early cellular changes that lead to cancer, in women with dense breasts.

Numerous studies have shown that women with denser breast tissue, and thus more gland tissue and less fatty tissue, are at higher risk for breast cancer. Moreover, as the American Cancer Society (ACS) explains, "Dense breast tissue can also make it harder for doctors to spot problems on mammograms." (ACS Guidelines.)

This is why five states -- California, Texas, New York, Connecticut and Virginia -- have passed legislation requiring that women whose mammograms show dense breasts must be notified of this fact, and several other states and the U.S. Congress are considering such legislation. For instance, the New York law, which took effect January 19, 2013, states that mammography patients with dense breasts must be told: "Your mammogram shows that your breast tissue is dense. Dense breast tissue is very common and is not abnormal. However, dense breast tissue can make it harder to find cancer on a mammogram and may also be associated with an increased risk of breast cancer."

One key study highlights those risks. Scientists at the University of California, San Francisco examined aspirated fluid from the breasts of 2,700 women between the ages of 25 to 65. This fluid contains duct cells, which are responsible for more than 90 percent of breast cancers. The study found that women with dense breasts were more than four times more likely than women without dense breasts to have a condition called atypical hyperplasia -- in which the cells seem to grow too quickly and pile up on each other. These atypical cells represent the first steps on the path to cancer. As a result, spotting these cells is not only key to detecting the risk of cancer in these women; it also opens the door to treating the condition and halting the progression to cancer.

"It is vital that we understand the limits of mammography and give women a better test -- one that is capable of detecting the earliest signs of precancer," said Steven C. Quay, M.D., Ph.D., FCAP, Atossa Genetics' Chairman of the Board and Chief Executive Officer.

In January, Atossa Genetics launched such a diagnostic: the ForeCYTE Breast Health Test. The test, cleared by the U.S. Food & Drug Administration, uses a breast pump called the Mammary Aspirate Specimen Cytology Test (MASCT) to painlessly collect miniscule amounts of fluid from the milk ducts in women's breasts, analyzes the duct cells for hyperplasia and other abnormalities, and analyzes for genetic mutations.

In essence, this test is like a Pap smear for cancer, spotting the earliest cellular warnings up to eight years before cancer can be detected by any other method. Women with dense breasts, therefore, could be monitored every year or so for signs of atypical hyperplasia. As long as the results come back negative, these women could lead normal lives without fear of cancer. But if hyperplasia is detected, women could be treated to reverse the condition.

"Just as Pap smears have reduced cervical cancer rates by over 75 percent, becoming the most successful screening test in medicine, this test can detect the precursor changes that lead to breast cancer -- and make prevention possible," says Quay. "We believe this test should be mandatory for women with dense breasts."

To use Atossa's ForeCYTE Breast Health System, see your doctor. The Atossa test is being distributed to health care providers nationwide by Clarity Women's Health (a division of Diagnostic Test Group, LLC) of Boca Raton, Florida. (See press release.)

For background and additional information on breast density legislation, see WSJ online.

Visit link:
Women With Dense Breasts Are at Higher Risk for Cancer

Recommendation and review posted by Bethany Smith